Via: Reuters
CNS-Related Edema Company Remedy Pharmaceuticals Strengthens Leadership Team in Preparation for Phase 3 Trial
Remedy Pharmaceuticals, a clinical stage pharmaceutical company focused on the development and commercialization of an innovative central nervous system drug, CIRARA™, announced today that the Company strengthened its leadership team with the appointment of Ann Tunstall as Vice President of Regulatory and Operational Affairs, and Alan Cutler as Vice President of Chemistry Manufacturing and Controls.
"We’re excited to have Ann and Alan join our executive team,” commented Sven Jacobson, CEO of Remedy Pharmaceuticals. “They bring a wealth of experience and tremendous knowledge, which we believe will be a great asset to the company as we move closer to initiating our Phase 3 trial targeting brain swelling following severe stroke. We also look forward to their contributions as we accelerate our clinical trial efforts in other CNS conditions where swelling is an important determinant of outcome such as spinal cord injury, traumatic brain injury and subarachnoid hemorrhage.”
Read More: http://www.reuters.com/article/ny-remedy-pharmaceutical-idUSnBw055226a+100+BSW20160105
RSS Feed
